Yeah who knows where this is going? Who knows how much of what has been told (regarding covid, vax, etc...) is true?
I fear that investors need not worry about covid going away too soon.
It seems that only the panic is gone from the pandemic. That will effect pps of all covid plays. We now live in a "comfortable with covid" world.
Still think there will be considerable revenue from covid, but the data & opportunity for a wide array of dosing & delivery sequences plus the diversity in trial participants may prove to be most valuable long term.
Imho, this will wind up being the most studied drug in history when you consider that many critical covid patients are likely on maintenance meds. Safety profile consisting of no severe side effects is great, but no drug interactions would make LL every pharma's prom date.
Throw in the other indications & you understand why Recknor is never satisfied that we know enough.